Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS
Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to th...
Gespeichert in:
| Veröffentlicht in: | PharmacoEconomics 2001, Vol.19 (12), p.1199-1208 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1208 |
|---|---|
| container_issue | 12 |
| container_start_page | 1199 |
| container_title | PharmacoEconomics |
| container_volume | 19 |
| creator | KEMPEN, John H FRICK, Kevin D JABS, Douglas A |
| description | Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective. |
| doi_str_mv | 10.2165/00019053-200119120-00002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72385450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72385450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-ca4d40d19abc4bfdcdce1f0051d03debeb50dfa902377a8f2b63ca09d873c6483</originalsourceid><addsrcrecordid>eNpFUctuFDEQtBCIPOAXkC9wm9C2Z8bjYxQCrBTEAThbHrvNGOaF7d2wf483uyQHd5faVaVWNSGUwRVnbfMeAJiCRlS8AKYYh6qMgD8j54xJVcZcPn_AUMlWwRm5SOlXYbRC8pfkrHxIzprmnOjNbCNOOGczUrukTNF7tDnscMaU6OLpGpd12I_mb0jUL5HafV4m_GnGZRfiNlEXEpqENMx0NTkUq0TvQx7o9ebDt1fkhTdjwtenfkl-fLz9fvO5uvv6aXNzfVfZuua5sqZ2NTimTG_r3jvrLDIP0DAHwmGPfQPOGwVcSGk6z_tWWAPKdVLYtu7EJXl39C3b_tliynoKyeI4mhmXbdKSi66pGyjE7ki0cUkpotdrDJOJe81AH8LV_8PVj-Hqh3CL9MtRGnFF-6i7_z2sA9pl1jstDFOl7Ms7qEsLhxkvZT0AppQuhp0e8lT83px23vYTuqdFTtcphLcngknWjD6a2Yb0xBM1KKak-AcH3J2o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72385450</pqid></control><display><type>article</type><title>Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS</title><source>MEDLINE</source><source>RePEc</source><source>Springer Nature - Complete Springer Journals</source><creator>KEMPEN, John H ; FRICK, Kevin D ; JABS, Douglas A</creator><creatorcontrib>KEMPEN, John H ; FRICK, Kevin D ; JABS, Douglas A</creatorcontrib><description>Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/00019053-200119120-00002</identifier><identifier>PMID: 11772155</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS-Related Opportunistic Infections - economics ; AIDS-Related Opportunistic Infections - prevention & control ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiretrovirals ; Antiviral agents ; Antiviral Agents - economics ; Antiviral Agents - therapeutic use ; Antivirals ; Azithromycin ; Biological and medical sciences ; Cost effectiveness ; Cost-Benefit Analysis ; Cotrimoxazole ; Cytomegalovirus infections ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - economics ; Cytomegalovirus Infections - prevention & control ; Economics, Pharmaceutical ; Fluconazole ; Ganciclovir ; Health technology assessment ; Humans ; Medical sciences ; Pharmacoeconomics ; Pharmacology. Drug treatments ; Quality-Adjusted Life Years</subject><ispartof>PharmacoEconomics, 2001, Vol.19 (12), p.1199-1208</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-ca4d40d19abc4bfdcdce1f0051d03debeb50dfa902377a8f2b63ca09d873c6483</citedby><cites>FETCH-LOGICAL-c442t-ca4d40d19abc4bfdcdce1f0051d03debeb50dfa902377a8f2b63ca09d873c6483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,3996,4012,27906,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13409197$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11772155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a19_3ay_3a2001_3ai_3a12_3ap_3a1199-1208.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>KEMPEN, John H</creatorcontrib><creatorcontrib>FRICK, Kevin D</creatorcontrib><creatorcontrib>JABS, Douglas A</creatorcontrib><title>Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><description>Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - economics</subject><subject>AIDS-Related Opportunistic Infections - prevention & control</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiretrovirals</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - economics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Azithromycin</subject><subject>Biological and medical sciences</subject><subject>Cost effectiveness</subject><subject>Cost-Benefit Analysis</subject><subject>Cotrimoxazole</subject><subject>Cytomegalovirus infections</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Cytomegalovirus Infections - economics</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Economics, Pharmaceutical</subject><subject>Fluconazole</subject><subject>Ganciclovir</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacoeconomics</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality-Adjusted Life Years</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><recordid>eNpFUctuFDEQtBCIPOAXkC9wm9C2Z8bjYxQCrBTEAThbHrvNGOaF7d2wf483uyQHd5faVaVWNSGUwRVnbfMeAJiCRlS8AKYYh6qMgD8j54xJVcZcPn_AUMlWwRm5SOlXYbRC8pfkrHxIzprmnOjNbCNOOGczUrukTNF7tDnscMaU6OLpGpd12I_mb0jUL5HafV4m_GnGZRfiNlEXEpqENMx0NTkUq0TvQx7o9ebDt1fkhTdjwtenfkl-fLz9fvO5uvv6aXNzfVfZuua5sqZ2NTimTG_r3jvrLDIP0DAHwmGPfQPOGwVcSGk6z_tWWAPKdVLYtu7EJXl39C3b_tliynoKyeI4mhmXbdKSi66pGyjE7ki0cUkpotdrDJOJe81AH8LV_8PVj-Hqh3CL9MtRGnFF-6i7_z2sA9pl1jstDFOl7Ms7qEsLhxkvZT0AppQuhp0e8lT83px23vYTuqdFTtcphLcngknWjD6a2Yb0xBM1KKak-AcH3J2o</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>KEMPEN, John H</creator><creator>FRICK, Kevin D</creator><creator>JABS, Douglas A</creator><general>Adis International</general><general>Springer Healthcare | Adis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2001</creationdate><title>Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS</title><author>KEMPEN, John H ; FRICK, Kevin D ; JABS, Douglas A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-ca4d40d19abc4bfdcdce1f0051d03debeb50dfa902377a8f2b63ca09d873c6483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - economics</topic><topic>AIDS-Related Opportunistic Infections - prevention & control</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiretrovirals</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - economics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Azithromycin</topic><topic>Biological and medical sciences</topic><topic>Cost effectiveness</topic><topic>Cost-Benefit Analysis</topic><topic>Cotrimoxazole</topic><topic>Cytomegalovirus infections</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Cytomegalovirus Infections - economics</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Economics, Pharmaceutical</topic><topic>Fluconazole</topic><topic>Ganciclovir</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacoeconomics</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality-Adjusted Life Years</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KEMPEN, John H</creatorcontrib><creatorcontrib>FRICK, Kevin D</creatorcontrib><creatorcontrib>JABS, Douglas A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KEMPEN, John H</au><au>FRICK, Kevin D</au><au>JABS, Douglas A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS</atitle><jtitle>PharmacoEconomics</jtitle><addtitle>Pharmacoeconomics</addtitle><date>2001</date><risdate>2001</risdate><volume>19</volume><issue>12</issue><spage>1199</spage><epage>1208</epage><pages>1199-1208</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior to the availability of highly active antiretroviral therapy (HAART) were unfavourable relative to other specific antimicrobial prophylactic strategies in patients with AIDS. With the availability of HAART, several inputs upon which previous estimates of the incremental cost-effectiveness ratio for anti-CMV prophylaxis were based probably changed substantially. To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to identify conditions under which prophylaxis for CMV disease in patients with AIDS could potentially become cost effective.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>11772155</pmid><doi>10.2165/00019053-200119120-00002</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1170-7690 |
| ispartof | PharmacoEconomics, 2001, Vol.19 (12), p.1199-1208 |
| issn | 1170-7690 1179-2027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72385450 |
| source | MEDLINE; RePEc; Springer Nature - Complete Springer Journals |
| subjects | Acquired Immunodeficiency Syndrome - drug therapy AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - economics AIDS-Related Opportunistic Infections - prevention & control Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiretrovirals Antiviral agents Antiviral Agents - economics Antiviral Agents - therapeutic use Antivirals Azithromycin Biological and medical sciences Cost effectiveness Cost-Benefit Analysis Cotrimoxazole Cytomegalovirus infections Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - economics Cytomegalovirus Infections - prevention & control Economics, Pharmaceutical Fluconazole Ganciclovir Health technology assessment Humans Medical sciences Pharmacoeconomics Pharmacology. Drug treatments Quality-Adjusted Life Years |
| title | Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incremental%20cost%20effectiveness%20of%20prophylaxis%20for%20cytomegalovirus%20disease%20in%20patients%20with%20AIDS&rft.jtitle=PharmacoEconomics&rft.au=KEMPEN,%20John%20H&rft.date=2001&rft.volume=19&rft.issue=12&rft.spage=1199&rft.epage=1208&rft.pages=1199-1208&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/00019053-200119120-00002&rft_dat=%3Cproquest_cross%3E72385450%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72385450&rft_id=info:pmid/11772155&rfr_iscdi=true |